Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

PMID:
25779953
2.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ.

Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1.

3.

S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Virk-Baker MK, Barnes S, Krontiras H, Nagy TR.

Nutr Res. 2014 Feb;34(2):116-25. doi: 10.1016/j.nutres.2013.12.002. Epub 2013 Dec 18.

4.

What is a clear margin in breast conserving cancer surgery?

Krontiras H, Lancaster RB, Urist MM.

Curr Treat Options Oncol. 2014 Mar;15(1):79-85. doi: 10.1007/s11864-013-0270-4. Review.

PMID:
24395277
5.

Socioeconomic disparities in breast cancer treatment among older women.

White A, Richardson LC, Krontiras H, Pisu M.

J Womens Health (Larchmt). 2014 Apr;23(4):335-41. doi: 10.1089/jwh.2013.4460. Epub 2013 Dec 19.

6.

Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.

Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR.

Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17.

7.

Harvest for health gardening intervention feasibility study in cancer survivors.

Blair CK, Madan-Swain A, Locher JL, Desmond RA, de Los Santos J, Affuso O, Glover T, Smith K, Carley J, Lipsitz M, Sharma A, Krontiras H, Cantor A, Demark-Wahnefried W.

Acta Oncol. 2013 Aug;52(6):1110-8. doi: 10.3109/0284186X.2013.770165. Epub 2013 Feb 26.

8.

How do I screen patients for breast cancer?

Krontiras H, Bramlett R, Umphrey H.

Curr Treat Options Oncol. 2013 Mar;14(1):88-96. doi: 10.1007/s11864-012-0218-0.

PMID:
23315271
9.

Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial.

Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H; Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group.

Contemp Clin Trials. 2013 Mar;34(2):282-95. doi: 10.1016/j.cct.2012.12.003. Epub 2012 Dec 22.

10.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

11.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

12.

Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.

De Los Santos J, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, Cantor A, Forero A.

Clin Breast Cancer. 2011 Oct;11(5):312-9. doi: 10.1016/j.clbc.2011.06.007. Epub 2011 Aug 10.

PMID:
21831721
13.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28.

14.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators.

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

15.

Image-guided methods for biopsy of suspicious breast lesions.

Vandromme MJ, Umphrey H, Krontiras H.

J Surg Oncol. 2011 Mar 15;103(4):299-305. doi: 10.1002/jso.21795. Review.

PMID:
21337562
16.

A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE.

Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149.

17.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
18.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

19.

Less-than-standard treatment in rectal cancer patients: which patients are at risk?

Pisu M, Richardson LC, Kim YI, Krontiras H, Martin MY, Salas M, Pollack LA.

J Natl Med Assoc. 2010 Mar;102(3):190-8.

PMID:
20355348
20.

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2010 Feb;8(2):xxxvii. Buys, Sandra [corrected to Buys, Saundra]; Yaneeklov, Thomas [corrected to Yankeelov, Thomas].

PMID:
19930975
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk